Eligible AACR 2019 Annual Meeting Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Updates in Immuno-oncology Trials

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8
Chairperson
Michael B Atkins
Georgetown Lombardi Comp. Cancer Ctr., Washington, DC, United States
from AACR Annual Meeting 2018 on April 16, 2018 3:00 PM-5:00 PM
Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
Rakesh Awasthi
Novartis Institutes for BioMedical Research, East Hanover, NJ, United States
from AACR Annual Meeting 2018 on April 16, 2018 3:00 PM-5:00 PM
Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial
Hyun Cheol Chung
Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea, Republic of
from AACR Annual Meeting 2018 on April 16, 2018 3:00 PM-5:00 PM
Durvalumab + tremelimumab in patients with metastatic urothelial cancer
Arjun V Balar
Perlmutter Cancer Center at NYU Langone Health, New York, NY, United States
from AACR Annual Meeting 2018 on April 16, 2018 3:00 PM-5:00 PM
Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC
Jamie Chaft
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2018 on April 16, 2018 3:00 PM-5:00 PM
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study
Yi-Long Wu
Guandong General Hospital, Guangzhou, China
from AACR Annual Meeting 2018 on April 16, 2018 3:00 PM-5:00 PM
Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma
Denis Soulieres
Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada
from AACR Annual Meeting 2018 on April 16, 2018 3:00 PM-5:00 PM
Nivolumab (Nivo) vs investigator’s choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141
Robert L Ferris
University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, United States
from AACR Annual Meeting 2018 on April 16, 2018 3:00 PM-5:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8